Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Olympus FLUOVIEW FVMPE-RS Multiphoton microscope series adds two new systems for imaging deep, rapidly changing biological specimens

Olympus has announced the release of two new configurations in its FLUOVIEW® FVMPE-RS multiphoton laser scanning microscope series -- a Gantry microscope system and an inverted microscope system.

From Evident Corporation - Life Sciences 9 Feb 2015

NMR and inhibiting HIV: an interview with Professor Michael Summers

Michael Summers is the Professor of Chemistry and Biochemistry at the University of Maryland, Baltimore County, and an investigator with the Howard Hughes Medical Institute. In this interview, he tells us about his work investigating the structure of large RNAs using NMR spectroscopy.

From Bruker BioSpin - NMR, EPR and Imaging 9 Feb 2015

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.

6 Feb 2015

MedImmune, University of Manchester sign new research collaboration

MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein formulation science.

5 Feb 2015

AstraZeneca announces research collaborations to use genome-editing tool for drug discovery and development

AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas.

30 Jan 2015

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

The Alzheimer's Drug Discovery Foundation announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI).

28 Jan 2015

Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

In a new research study, scientists from Vision Genomics, LLC, Insilico Medicine, Inc., and Howard University showed that Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) is comparable to normal aging with respect to cellular signaling pathways, and that HGPS truly recapitulates the normal aging process.

28 Jan 2015

Biolin Scientific acquires the key patent protecting multi-hole, high-throughput ion channel screening

Biolin Scientific today announces the acquisition of a key patent related to performing multi-hole, high-throughput ion channel screening.

27 Jan 2015

Removing volatile organic solvents from your 96-well microplates in minutes

The MiniVap™ blowdown evaporator from Porvair Sciences takes just minutes to remove volatile organic solvents from your 96-well microplates. The MiniVap™ is the perfect tool for labs where smaller numbers of individual plates need drying.

From Chromatrap® - Porvair Sciences Ltd 26 Jan 2015

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.

23 Jan 2015

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, announces significant progress in its drug discovery collaboration with AstraZeneca.

22 Jan 2015

Penn researchers make breakthrough on novel anesthetics

Penn Medicine researchers, in a continuation of their groundbreaking work to better understand how anesthesia works in the body, have found the first new class of novel anesthetics since the 1970s. Their findings, published in February issue of Anesthesiology, detail the processes through which the group uncovered these compounds.

21 Jan 2015

AMRI awarded NIH contract for drug development services

AMRI today announced it received a 10-year federal contract award from the National Institutes of Health for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke award will support NIH's Drug Manufacturing and Formulation Program (DMFP), which is a component of the Blueprint Neurotherapeutics Network (BPN).

19 Jan 2015

Abnormal attachment of sugar to BACE1 enzyme leads to formation of Aβ plaques in the brain

Researchers at the RIKEN-Max Planck Joint Research Center in Japan have demonstrated that hallmark symptoms of Alzheimer's disease can be reduced when sugars are prevented from binding to one of the key enzymes implicated in the disease. The new findings, reported in EMBO Molecular Medicine, show that abnormal attachment of a particular sugar to the enzyme BACE1 is a critical factor leading to the formation of Aβ plaques in the brain, and that plaques were reduced and cognitive performance improved when this action was prevented in mice through loss of the enzyme GnT-III.

17 Jan 2015

BellBrook Labs announces launch of new Transcreener UDP TR-FRET Assay

BellBrook Labs, a leader in high throughput screening assays for drug discovery, announced the launch of a TR-FRET (time resolved Forster resonance energy transfer) version of the company's Transcreener UDP Assay, a high throughput screening assay for glycosyltransferases and other UDP-producing enzymes.

15 Jan 2015

Crown's first European symposium to focus on use of Translational Platforms in oncology drug discovery

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced its first European symposium, detailing the use of Translational Platforms including Patient-Derived Xenograft (PDX) models in oncology drug discovery and development. The conference will be held on Wednesday 11th February, at the headquarters of One Nucleus in Cambridge, UK and will welcome experts from renowned pharmaceutical companies and prominent academics working in oncology.

15 Jan 2015

QDREC software may help find effective treatment for schistosomiasis

For decades, scientists around the world have worked to develop a treatment for schistosomiasis, a debilitating water-born parasite that affects more than 200 million people worldwide. To aid this research, Rahul Singh, professor of computer science at San Francisco State University, has developed software that solves the key challenge of quantitatively assessing the impact of a drug on the parasite.

14 Jan 2015

MGB Biopharma provides update on business performance for 2014

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, provides an update on its business performance for 2014. MGB Biopharma is developing a pipeline of novel antimicrobials that puts it at the forefront of addressing the major global problem of antimicrobial resistance.

12 Jan 2015

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines.

From Precision NanoSystems Inc. 11 Jan 2015

Crown Bioscience to double capacity of PRECOS facility, rename UK site

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced that it will double the capacity of the recently acquired PRECOS (Preclinical Oncology Services Limited) facility and will rename the site Crown Bioscience UK Ltd.

9 Jan 2015